Feasibility of pharmacometabolomics to identify potential predictors of paclitaxel pharmacokinetic variability.
Li ChenCiao-Sin ChenYihan SunN Lynn HenryKathleen A StringerDaniel Louis HertzPublished in: Cancer chemotherapy and pharmacology (2021)
This study identified pretreatment metabolites that may be associated with paclitaxel PK variability demonstrating feasibility of a pharmacometabolomics approach for understanding paclitaxel PK. However, identification of more robust pharmacometabolomic predictors will be required for broad and routine application for the clinical dosing of paclitaxel.